Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Patients with significant kidney or liver disease would typically require closer monitoring
We work directly with your insurance company to get approval, saving you time and reducing confusion
GLP-1 attenuates intestinal fat absorption and chylomicron production via vagal afferent nerves originating in the portal vein
October 2021
GLP-1R triggers various intracellular signaling pathways, such as the cAMP/PKA and PI3K/Akt pathways, by binding to endogenous GLP-1 or exogenous agonists, resulting in the enhancement of insulin secretion, inhibition of glucagon secretion, as well as anti-inflammatory and antioxidant stress response
Press release - intarcia announces FDA filing acceptance of new drug application (NDA) for ITCA 650 for the treatment of type 2 diabetes
US$ 27.87
US$ 28.59
US$ 20.08
